Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1806 | TNBC | Basal A | Epirubicin | TOP2 | TOP | 172 | uM | 7830.017 | 0.0002 | -0.9837 | 1.7247 | |
| MDA-MB-175-VII | HR+ | Luminal | Fascaplysin | CDK4 | CDK | 33.3 | uM | 7499.084 | 0.0003 | -0.9999 | 0.7991 | |
| HCC1187 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7432.074 | 0.0003 | -0.9998 | 0.8598 | |
| HCC1187 | TNBC | Basal A | Fascaplysin | CDK4 | CDK | 33.3 | uM | 7432.084 | 0.0003 | -0.9998 | 0.8538 | |
| MCF7 | HR+ | Luminal | Epirubicin | TOP2 | TOP | 172 | uM | 7875.017 | 0.0003 | -0.9878 | 1.6110 | |
| Hs 578T | TNBC | Basal B | Epirubicin | TOP2 | TOP | 172 | uM | 7861.017 | 0.0003 | -0.9757 | 1.8068 | |
| MDA-MB-231 | TNBC | Basal B | Fascaplysin | CDK4 | CDK | 33.3 | uM | 7504.084 | 0.0003 | -0.9722 | 1.8866 | |
| MDA-MB-453 | TNBC | Luminal | Epirubicin | TOP2 | TOP | 172 | uM | 9708.017 | 0.0003 | -0.9990 | 1.0949 | |
| MDA-MB-453 | TNBC | Luminal | Epirubicin | TOP2 | TOP | 172 | uM | 7903.017 | 0.0003 | -0.9984 | 1.1625 | |
| MDA-MB-468 | TNBC | Basal A | Epirubicin | TOP2 | TOP | 172 | uM | 7905.035 | 0.0003 | -0.9999 | 0.8588 | |
| MCF12A | NM | Basal B | Doxorubicin | TOP2 | TOP | 92 | uM | 7491.078 | 0.0003 | -1.0000 | 0.7238 | |
| MDA-MB-231 | TNBC | Basal B | Epirubicin | TOP2 | TOP | 172 | uM | 7892.017 | 0.0003 | -0.9294 | 2.4495 | |
| SUM1315MO2 | TNBC | Basal B | Epirubicin | TOP2 | TOP | 172 | uM | 9797.017 | 0.0003 | -1.0000 | 0.4824 | |
| SUM149PT | TNBC | Basal B | 17-AAG | HSP90 | HSP90 | 100 | uM | 7917.05 | 0.0003 | -0.8935 | 2.7707 | |
| 184A1 | NM | Basal | Doxorubicin | TOP2 | TOP | 86.2 | uM | 10002.034 | 0.0003 | -1.0000 | 0.6736 | |
| SUM159PT | TNBC | Basal B | Disulfiram | Proteasome | Proteasome | 66.7 | uM | 13004.174 | 0.0003 | -0.8406 | 3.2757 | |
| HCC1187 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7432.074 | 0.0003 | -0.9998 | 0.8598 | |
| HCC38 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7469.074 | 0.0003 | -0.9663 | 1.9843 | |
| MCF 10F | NM | - | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7872.007 | 0.0003 | -0.9824 | 1.7126 | |
| HCC38 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7469.074 | 0.0003 | -0.9663 | 1.9843 | |
| SUM52PE | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 7540.078 | 0.0003 | -0.9997 | 0.9523 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7495.074 | 0.0003 | -0.9983 | 1.1729 | |
| MCF 10F | NM | - | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7872.007 | 0.0003 | -0.9824 | 1.7126 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7495.074 | 0.0003 | -0.9983 | 1.1729 | |
| MDA-MB-361 | HER2amp | Luminal | Disulfiram | Proteasome | Proteasome | 66.7 | uM | 12989.174 | 0.0003 | -1.0000 | 0.7084 |